reviewAnnals of MedicineJun 5, 2014Closed access

PI3K/AKT signaling pathway and cancer: an updated review

MMMiriam MartiniMCMaria Chiara De SantisLBLaura BracciniFGFederico GulluniEHEmilio Hirsch

University of Turin

PubMed
Indexed incrossrefdoajpubmed

Abstract

Despite development of novel agents targeting oncogenic pathways, matching targeted therapies to the genetic status of individual tumors is proving to be a daunting task for clinicians. To improve the clinical efficacy and to reduce the toxic side effects of treatments, a deep characterization of genetic alterations in different tumors is required. The mutational profile often evidences a gain of function or hyperactivity of phosphoinositide 3-kinases (PI3Ks) in tumors. These enzymes are activated downstream tyrosine kinase receptors (RTKs) and/or G proteins coupled receptors (GPCRs) and, via AKT, are able to induce mammalian target of rapamycin (mTOR) stimulation. Here, we elucidate the impact of class I…

Citation impact

1,192
total citations
FWCI
23.33
Percentile
100%
References
149
Citations per year

Authors

5

Topics & keywords

Topics
Keywords
  • PI3K/AKT/mTOR pathway
  • Receptor tyrosine kinase
  • Protein kinase B
  • Signal transduction
  • Biology
  • MAPK/ERK pathway
  • Phosphoinositide 3-kinase
  • Cancer research
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding